Home Biosimilar Antibodies Immunology & Inflammation CD markers inhibitor Praluzatamab ravtansine For research use only.
Not for use in humans.

Praluzatamab ravtansine

Synonyms: CX-2009

Praluzatamab ravtansine (CX-2009) is a conditionally activated Probody drug conjugate (PDC) comprising an anti-CD166 mAb conjugated to DM4, with a protease-cleavable linker and a peptide mask that limits target engagement in normal tissue and circulation.

Praluzatamab ravtansine

CAS No. 2145115-85-9

Purity & Quality Control

≥99

Choose Selective CD markers Inhibitors

Biological Activity

Description Praluzatamab ravtansine (CX-2009) is a conditionally activated Probody drug conjugate (PDC) comprising an anti-CD166 mAb conjugated to DM4, with a protease-cleavable linker and a peptide mask that limits target engagement in normal tissue and circulation.

Product Details

CAS No. 2145115-85-9
ADC antiody Praluzatamab
ADC cytotoxin DM4
Formulation 1xPBS
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Praluzatamab ravtansine | Praluzatamab ravtansine supplier | purchase Praluzatamab ravtansine | Praluzatamab ravtansine cost | Praluzatamab ravtansine manufacturer | order Praluzatamab ravtansine | Praluzatamab ravtansine distributor